Merck, Hit With First Fosamax Verdict, Challenges Plaintiff's Closing Arguments
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm hopes to negate $8 million verdict through post-trial motions.
You may also be interested in...
Merck Wins Second Fosamax Trial After Questioning Qualifications Of Expert Witness
After two bellwether cases, Merck has yet to lose and the next case involves a company-chosen defendant.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Bayer/J&J's Xarelto Approval For Stroke Prevention Sets Up Marketing Battle With Pradaxa
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: